购物车
- 全部删除
- 您的购物车当前为空
Bozitinib (PLB-1001) 是一种可透过血脑屏障的、高效的、选择性的的、 ATP 竞争性的小分子 c-MET 激酶抑制剂,能够与酪氨酸激酶超家族的常规 ATP 结合口袋结合。
为众多的药物研发团队赋能,
让新药发现更简单!
Bozitinib (PLB-1001) 是一种可透过血脑屏障的、高效的、选择性的的、 ATP 竞争性的小分子 c-MET 激酶抑制剂,能够与酪氨酸激酶超家族的常规 ATP 结合口袋结合。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 823 | 现货 | |
5 mg | ¥ 2,320 | 现货 | |
10 mg | ¥ 3,560 | 现货 | |
25 mg | ¥ 5,780 | 现货 | |
50 mg | ¥ 8,290 | 现货 | |
100 mg | ¥ 10,900 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 2,550 | 现货 |
产品描述 | Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability. Bozitinib binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily. |
体外活性 | Bozitinib (30 μM; 6 hours) inhibits the phosphorylation of MET and STAT3. Bozitinib has a robust inhibitory effect on MET and its downstream signaling pathways. |
别名 | PLB-1001, CBT-101 |
分子量 | 424.38 |
分子式 | C20H15F3N8 |
CAS No. | 1440964-89-5 |
Smiles | Cn1cc2cc(c(F)cc2n1)C(F)(F)c1nnc2ccc(nn12)-c1cnn(c1)C1CC1 |
密度 | 1.68 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 47 mg/mL (110.74 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容